Two Sigma Investments LP increased its stake in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 14.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,869 shares of the company’s stock after buying an additional 7,773 shares during the period. Two Sigma Investments LP owned 0.27% of Selecta Biosciences worth $587,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of SELB. Keybank National Association OH acquired a new position in Selecta Biosciences during the 4th quarter worth about $143,000. Two Sigma Advisers LP acquired a new position in Selecta Biosciences during the 4th quarter worth about $143,000. SG Americas Securities LLC acquired a new position in Selecta Biosciences during the 4th quarter worth about $145,000. Wells Fargo & Company MN lifted its position in Selecta Biosciences by 125.8% during the 4th quarter. Wells Fargo & Company MN now owns 23,491 shares of the company’s stock worth $230,000 after buying an additional 13,086 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new position in Selecta Biosciences during the 4th quarter worth about $243,000. Institutional investors and hedge funds own 50.16% of the company’s stock.
Selecta Biosciences stock opened at $12.70 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 9.00 and a current ratio of 9.00. Selecta Biosciences Inc has a 1 year low of $7.95 and a 1 year high of $24.02. The stock has a market cap of $224.84, a price-to-earnings ratio of -3.97 and a beta of -3.56.
SELB has been the topic of a number of research reports. Canaccord Genuity restated a “buy” rating and set a $30.00 target price on shares of Selecta Biosciences in a research report on Thursday, January 18th. ValuEngine downgraded shares of Selecta Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Mizuho initiated coverage on shares of Selecta Biosciences in a research report on Monday, February 26th. They set a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, BidaskClub upgraded shares of Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $23.33.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.